Structure and function of somatostatin receptors in growth hormone control.

Abstract

This new generation of SRIF analogs offer exciting opportunities to improve hormone hypersecretion in patients with GH- and TSH-secreting pituitary adenomas and possibly even in patients harboring prolactinomas and non-functioning tumors. Future development of novel analogs with improved affinity for both SSTR2 and SSTR5 may have even greater potency to suppress pituitary hormone hypersecretion and block adenoma growth.

• Authors: I Shimon, S Melmed
• Journal: The Journal of endocrinology (J Endocrinol) Vol. 155 Suppl 1 Pg. S3-6; discussion S7-8 (Oct 1997) ISSN: 0022-0795 [Print] England
• PMID: 9389989 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Hormones
• Peptides, Cyclic
• Receptors, Somatostatin
• lanreotide
• Somatostatin
• Growth Hormone
• Octreotide

Topics

• Adenoma (drug therapy, metabolism)
• Antineoplastic Agents (metabolism, therapeutic use)
• Cells, Cultured
• Growth Hormone (metabolism)
• Hormones (metabolism, therapeutic use)
• Humans
• Octreotide (analogs & derivatives, metabolism, therapeutic use)
• Peptides, Cyclic (metabolism, therapeutic use)
• Pituitary Gland (embryology, metabolism)
• Pituitary Neoplasms (drug therapy, metabolism)
• Protein Binding
• Receptors, Somatostatin (physiology)
• Somatostatin (analogs & derivatives, metabolism, therapeutic use)
• Structure-Activity Relationship